Development of a FLP/frt system for generating helper-dependent adenoviral vectors

Molecular Therapy

Volumn 3, Issue 5, 2001, Pages 809-815

  Ng, Philip ^a   Beauchamp, Cindy ^a   Evelegh, Carole ^a   Parks, Robin ^a   Graham, Frank L ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Adenovirus; Cre recombinase; FLP recombinase; Gene therapy; Helper virus; Helper dependent adenoviral vector

Indexed keywords

RECOMBINASE; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; CATALYSIS; CONTAMINATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE THERAPY; GENETIC RECOMBINATION; HELPER VIRUS; HUMAN; HUMAN CELL; VIRUS RECOMBINANT;

EID: 0034981674     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2001.0323     Document Type: Article

References (29)

1. Development of adenovirus vectors for expression of heterologous genes
2. Adenovirus-based expression vectors and recombinant vaccines
3. Human adenovirus vectors for gene transfer into mammalian cells
4. Structure and genetic organization of adenovirus vectors
5. Characteristics of a human cell line transformed by DNA from human adenovirus 5
6. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ
7. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration
8. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: Comparison of E2a wildtype and E2a deleted vectors
9. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression
10. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
11. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
12. Upregulation of class 1 major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo
13. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: Implications for gene therapy
14. Persistence in muscle of an adenoviral vector that lacks all viral genes
15. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of α1-antitrypsin with negligible toxicity
16. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene
17. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity
18. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver directed gene transfer in baboons
19. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector
20. Helper-dependent adenovirus vectors: Their use as a gene delivery system to neurons
21. Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector
22. A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal
23. Recombination with the yeast 2μ plasmid is site specific
24. Optimization of the helper-dependent adenovirus system for production and potency in vivo
25. Characteristics of a human cell line transformed by DNA from human adenovirus 5
26. Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre
27. A new technique for the assay of infectivity of human adenovirus 5 DNA
28. The yeast recombinase flp functions effectively in human cells for construction of adenovirus vectors
29. Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: A molecular switch for control of gene expression